MedTrace Logo

A Comparative Study of Salvage Treatment With Combination of Docetaxel and Epirubicin

NCT01624025 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2016-08-17

No results posted yet for this study

Summary

A salvage treatment with combination of docetaxel and epirubicin in patients with unresectable, metastatic gastric cancer after fluoropyrimidine failure : A HER2 status-based study

Conditions

  • Metastatic Advanced Gastric Cancer

Interventions

OTHER

Docetaxel 60 mg/m2, epirubicin 60 mg/m2, q3wks

Both the patients with HER2 (+) and HER2 (-) patients will be treated with the same regimen.

Sponsors & Collaborators

  • Yonsei University

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-06-30
Primary Completion
2015-09-30
Completion
2016-02-29

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01624025 on ClinicalTrials.gov